Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadalafil - Eli Lilly

Drug Profile

Tadalafil - Eli Lilly

Alternative Names: Adcirca; Cialis; GF 196960; IC 351; LY 450190; Zalutia

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; ICOS Corporation
  • Developer Eli Lilly; Gilead Sciences; GlaxoSmithKline; ICOS Corporation; Northwestern University; United Therapeutics Corporation
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Pyridones; Small molecules; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Duchenne muscular dystrophy
  • No development reported Raynaud's disease
  • Discontinued Angina pectoris; Female sexual dysfunction; Gastroparesis; Heart failure

Most Recent Events

  • 20 Nov 2017 The US FDA grants paediatric exclusivity for Tadalafil tablets through May 21, 2018 for use in paediatric patients with Duchenne muscular dystrophy
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Raynaud's-disease in USA (PO)
  • 22 Aug 2017 Eli Lilly enters into a settlement agreement with Argentum Pharmaceuticals related to marketing of generic Tadalafil
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top